According to the new research report published by Precedence Research, titled “Generic Injectable Market (By Product Type: Chemotherapy agents, Small molecule antibiotics, Vaccines, Peptide antibiotics, Blood factors, Peptide hormone, Insulin, Cytokines, Immunoglobin, Monoclonal Antibodies; By Molecular Type: Small Molecule, Large Molecule; By Application; By Administration; By Distribution Channel) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030”, the global generic injectable market size is expected to be worth around US$ 309.1 billion by 2030 and is poised to record a yearly growth rate of 14.01% from 2022 to 2030. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on generic injectable market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall generic injectable market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
Key Takeaway:
- The large molecule type segment has held 69% revenue share in 2021.
- The small molecule segment accounted 31% market share in 2021.
- North America region has dominated the market with revenue share of around 46% in 2021.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2180
The study also provides important advancements in organic and inorganic growth strategies in the worldwide generic injectable market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of generic injectable market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Report Scope of the Generic Injectable Market
| Report Coverage | Details |
| Market Size in 2022 | USD 107.6 Billion |
| Market Size by 2030 | USD 309.1 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 14.1% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Product Type, Molecular Type, Application, Administration, Distribution Channel, and Geography |
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the generic injectable market.
Some of the prominent players in the generic injectable market include:
- DR. Reddys Laboratries Ltd
- Baxter International
- Mylan N.A
- Teva Pharmaceuticals
- Astra Zeneca Plc
- Sanofi S.A
- Fresenius Kabi
- Pfizer Inc
- Cipla Ltd
- Merck & Co. Inc
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Samsung Biologics Co Ltd
- Biocon
- Lupin,Ltd
- Astrazeneca
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals
- Cosette Pharmaceutical, Inc
- Johnson & Johnson Services, Inc
- Sanofi SA
- Amgen Inc.
- Bristol- Myers Squibb Company
- Piramal Pharma Solutions
- Merck KGaA
Market Segmentations
By Product Type
- Chemotherapy agents
- Small molecule antibiotics
- Vaccines
- Peptide antibiotics
- Blood factors
- Peptide hormone
- Insulin
- Cytokines
- Immunoglobin
- Monoclonal Antibodies
By Molecular Type
- Small Molecule
- Large Molecule
By Application
- Oncology
- Diabetes
- Infectious Diseases
- Blood Disorders
- Musculoskeletal Disorders
- Hormonal Disorders
- Pain Management
- CNS Diseases
- Cardiovascular Diseases
By Administration
- Intravenous (IV)
- Intramuscular (IM)
- Subcutaneous (SC)
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Drug stores
- Online pharmacy
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, segment, and project the global market size for generic injectable market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyze the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyze their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyze the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generic Injectable Market
5.1. COVID-19 Landscape: Generic Injectable Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generic Injectable Market, By Product Type
8.1. Generic Injectable Market, by Product Type, 2022-2030
8.1.1. Chemotherapy agents
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Small molecule antibiotics
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Peptide antibiotics
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Blood factors
8.1.5.1. Market Revenue and Forecast (2017-2030)
8.1.6. Peptide hormone
8.1.6.1. Market Revenue and Forecast (2017-2030)
8.1.7. Insulin
8.1.7.1. Market Revenue and Forecast (2017-2030)
8.1.8. Cytokines
8.1.8.1. Market Revenue and Forecast (2017-2030)
8.1.9. Immunoglobin
8.1.9.1. Market Revenue and Forecast (2017-2030)
8.1.10. Monoclonal Antibodies
8.1.10.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Generic Injectable Market, By Molecular Type
9.1. Generic Injectable Market, by Molecular Type, 2022-2030
9.1.1. Small Molecule
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Large Molecule
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Generic Injectable Market, By Application
10.1. Generic Injectable Market, by Application, 2022-2030
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Diabetes
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Infectious Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Blood Disorders
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Musculoskeletal Disorders
10.1.5.1. Market Revenue and Forecast (2017-2030)
10.1.6. Hormonal Disorders
10.1.6.1. Market Revenue and Forecast (2017-2030)
10.1.7. Pain Management
10.1.7.1. Market Revenue and Forecast (2017-2030)
10.1.8. CNS Diseases
10.1.8.1. Market Revenue and Forecast (2017-2030)
10.1.9. Cardiovascular Diseases
10.1.9.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Generic Injectable Market, By Administration
11.1. Generic Injectable Market, by Administration, 2022-2030
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Intramuscular (IM)
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Intramuscular (IM)
11.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Generic Injectable Market, By Distribution Channel
12.1. Generic Injectable Market, by Distribution Channel, 2022-2030
12.1.1. Hospital pharmacy
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Hospital pharmacy
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Drug stores
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Online pharmacy
12.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Generic Injectable Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.6.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.1.7.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.1.7.3. Market Revenue and Forecast, by Application (2017-2030)
13.1.7.4. Market Revenue and Forecast, by Administration (2017-2030)
13.1.7.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.7. Market Revenue and Forecast, by Administration (2017-2030)
13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.10. Market Revenue and Forecast, by Administration (2017-2030)
13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Application (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Administration (2017-2030)
13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Application (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Administration (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Molecular Type (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Application (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Administration (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 14. Company Profiles
14.1. DR. Reddys Laboratries Ltd
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Baxter International
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Mylan N.A
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Teva Pharmaceuticals
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Teva Pharmaceuticals
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Fresenius Kabi
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Cipla Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Merck & Co. Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global generic injectable market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for generic injectable are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
